Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Newborn Screening Mld topic
No spam. Unsubscribe anytime.
Committee hears personal testimony urging addition of MLD to newborn screening; bill laid over
Summary
The Health Finance and Policy Committee heard emotional testimony from a mother and clinicians urging that metachromatic leukodystrophy (MLD) be added to Minnesota's newborn screening panel. Lawmakers discussed federal and state review processes; the chair laid House File 1029 over for possible inclusion in an omnibus bill.
A bill to add metachromatic leukodystrophy, or MLD, to Minnesota's newborn screening panel drew emotional testimony Wednesday as the Health Finance and Policy Committee considered House File 10‑29.
Representative Paul Torkelson presented the bill and said it is intended to give families affected by rare diseases “a chance ... to share their voice with the legislature and ... highlight how important this work is.”
Erica Barnes testified on her own behalf about her daughter, Chloe, who was diagnosed with MLD after a period of developmental decline. Barnes recounted Chloe's diagnosis and death in 2010 and described recent scientific advances that have produced effective treatments. “Please pass this bill and add MLD to the newborn screening panel,” Barnes told the committee.
Jennifer Braun, a nurse practitioner and clinical director at the University of Minnesota pediatric blood and marrow transplant program, told the panel that clinicians often only identify MLD once a child shows symptoms and that, by then, “there's typically nothing that we can do for them.” She said new treatments can help presymptomatic children and argued that “we need newborn screening. We need an ability to identify these patients before they develop symptoms so that we can treat them thoroughly.”
Members asked about the relationship between the federal recommended newborn screening list and Minnesota's state panel. Torkelson said Minnesota typically follows the federal list but can and sometimes does add conditions beyond it. Committee members were told the state's newborn screening decision-makers recently reconsidered MLD and would review it again at their next meeting.
No public opponents appeared. After roughly five minutes of member questions, Chair Bakker moved the bill before the committee with the intent to lay it over for possible inclusion in an omnibus bill; the committee laid House File 10‑29 over for possible inclusion.
Why it matters: MLD is a rare, aggressive neurodegenerative disorder that causes severe disability in young children. Witnesses described new therapies that can improve outcomes if patients are identified before symptoms begin, and supporters said adding MLD to newborn screening would let clinicians identify and treat children earlier.
The committee did not take a final vote on the bill; the chair’s stated action was to lay the bill over for possible omnibus inclusion.
